Window of data and olap in unicauca virtual

The analysis of information has become one of the most important processes in major enterprises which manage a high number of customers. These Enterprises have found in the information generated by its own systems, valuable knowledge that might help to improve inner processes, customer relationship, competitiveness, cost cutting and revenue increase, etc. However, not only the major enterprises with industrial process and great quantity of customer, find the analysis of information; useful there are successful cases this kind of technology in other areas like transport, health, biology, chemistry, genetic, and education. This is why University of Cauca, sponsored by The Information Technology Group and Colciencias, has begun a project that implements a Decision Support System (DSS), that let directives and teachers of Unicauca Virtual, use the data warehouse potentiality and OLAP technologies to analyze information generated between students and the Learning Management System (LMS) of Unicauca Virtual. This article, present the development processes of this project emphasizing in modeling and construction of the data warehouse in the Oracle 10g Release2 database engine.El análisis de información se ha convertido en uno de los procesos más importantes de la mayoría de empresas que manejan gran cantidad de clientes. Ellas, han encontrado en la información generada por sus propios sistemas, conocimiento valioso que les puede ayudar a mejorar sus procesos internos, mejorar la relación con los clientes, ser más competitivos, minimizar costos e incrementar utilidades entre muchas otras cosas. Sin embargo, no solamente en las empresas grandes, con procesos industriales y gran cantidad de clientes es útil el análisis de información, existen casos exitosos del uso de tecnologías de análisis en áreas como el transporte, la medicina, la biología, la química, la genética y por supuesto la educación. Es así como en la Universidad del Cauca, apoyados por el Grupo de I+D en Tecnologías de la información y Colciencias, se ha iniciado un proyecto en el cual se pretende implementar un Sistema de Soporte a la toma de Decisiones (DSS), que permita a directivos y profesores de Unicauca Virtual (Universidad Virtual del Cauca), utilizar la potencialidad de las tecnologías Data Warehouse y OLAP en el análisis de información generadas en la interacción del estudiante y el sistema gestor de aprendizaje (LMS) de Unicauca Virtual. Este artículo presenta el proceso de desarrollo de este proyecto haciendo énfasis en el modelado y la construcción de la bodega de datos en el motor de base de datos Oracle 10g Release 2

Web mobile en el soporte a actividades de muestreo en laboratorios de análisis de muestras

Los sistemas de información (SI) en los laboratorios de análisis de muestras facilitan la gestión para la obtención de la acreditación según la norma ISO 17025. Sin embargo, existen procesos que dificultan el uso de SI convencionales, como lo es el muestreo. La implementación de  un sistema de información móvil (SIM) como apoyo a los SI en los laboratorios puede resultar en una solución para soportar el muestreo. En este artículo se ilustra el desarrollo de un SIM usando web mobile para el apoyo al muestreo en un laboratorio de la Universidad Industrial de Santander (UIS)

Herramienta computacional para la documentación de pruebas de software enmarcado en actividades de investigación

El presente artículo describe el diseño de una herramienta computacional para la documentación de pruebas de software. La herramienta permite gestionar documentos como el plan maestro de pruebas; los planes de nivel, casos  y procedimientos de prueba; reporte de anomalías y reporte de pruebas, que hacen parte de una adecuada documentación de pruebas de software. Utilizando diagrama de paquetes  y casos de uso se muestra la funcionalidad disponible en la herramienta, la cual ha sido diseñada a partir de la norma IEEE 829

Web mobile en el soporte a actividades de muestreo en laboratorios de análisis de muestras

Los sistemas de información (SI) en los laboratorios de análisis de muestras facilitan la gestión para la obtención de la acreditación según la norma ISO 17025. Sin embargo, existen procesos que dificultan el uso de SI convencionales, como lo es el muestreo. La implementación de  un sistema de información móvil (SIM) como apoyo a los SI en los laboratorios puede resultar en una solución para soportar el muestreo. En este artículo se ilustra el desarrollo de un SIM usando web mobile para el apoyo al muestreo en un laboratorio de la Universidad Industrial de Santander (UIS)

Web mobile en el soporte a actividades de muestreo en laboratorios de análisis de muestras

Los sistemas de información (SI) en los laboratorios de análisis de muestras facilitan la gestión para la obtención de la acreditación según la norma ISO 17025. Sin embargo, existen procesos que dificultan el uso de SI convencionales, como lo es el muestreo. La implementación de  un sistema de información móvil (SIM) como apoyo a los SI en los laboratorios puede resultar en una solución para soportar el muestreo. En este artículo se ilustra el desarrollo de un SIM usando web mobile para el apoyo al muestreo en un laboratorio de la Universidad Industrial de Santander (UIS)

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment

Background: High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010. Methods: We used data for exposure to risk factors by country, age group, and sex from pooled analyses of population-based health surveys. We obtained relative risks for the effects of risk factors on cause-specific mortality from meta-analyses of large prospective studies. We calculated the population attributable fractions for each risk factor alone, and for the combination of all risk factors, accounting for multicausality and for mediation of the effects of BMI by the other three risks. We calculated attributable deaths by multiplying the cause-specific population attributable fractions by the number of disease-specific deaths. We obtained cause-specific mortality from the Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. We propagated the uncertainties of all the inputs to the final estimates. Findings: In 2010, high blood pressure was the leading risk factor for deaths due to cardiovascular diseases, chronic kidney disease, and diabetes in every region, causing more than 40% of worldwide deaths from these diseases; high BMI and glucose were each responsible for about 15% of deaths, and high cholesterol for more than 10%. After accounting for multicausality, 63% (10·8 million deaths, 95% CI 10·1-11·5) of deaths from these diseases in 2010 were attributable to the combined effect of these four metabolic risk factors, compared with 67% (7·1 million deaths, 6·6-7·6) in 1980. The mortality burden of high BMI and glucose nearly doubled from 1980 to 2010. At the country level, age-standardised death rates from these diseases attributable to the combined effects of these four risk factors surpassed 925 deaths per 100 000 for men in Belarus, Kazakhstan, and Mongolia, but were less than 130 deaths per 100 000 for women and less than 200 for men in some high-income countries including Australia, Canada, France, Japan, the Netherlands, Singapore, South Korea, and Spain. Interpretation: The salient features of the cardiometabolic disease and risk factor epidemic at the beginning of the 21st century are high blood pressure and an increasing effect of obesity and diabetes. The mortality burden of cardiometabolic risk factors has shifted from high-income to low-income and middle-income countries. Lowering cardiometabolic risks through dietary, behavioural, and pharmacological interventions should be a part of the global response to non-communicable diseases. Funding: UK Medical Research Council, US National Institutes of Health. © 2014 Elsevier Ltd